The main treatments for Guillain-Barré Syndrome (GBS) are plasmapheresis and intravenous immunoglobulin (IVIg).
While both treatments are considered equally effective, they work through different mechanisms to reduce the severity and duration of GBS. Here's a breakdown:
-
Plasmapheresis (Plasma Exchange): This procedure removes harmful antibodies from the blood plasma that are attacking the nerves. It's like filtering the blood to remove the substances causing the damage. While effective, it generally takes longer than IVIg to administer.
-
Intravenous Immunoglobulin (IVIg): IVIg involves administering high doses of antibodies obtained from healthy donors. These antibodies help to neutralize the harmful antibodies attacking the nerves and modulate the immune system.
Both plasmapheresis and IVIg are typically administered in the hospital setting, and the choice of treatment depends on various factors, including the severity of the GBS, the patient's overall health, and the availability of resources. It's essential to consult with a healthcare professional to determine the most appropriate treatment plan.
